GOLDMAN SACHS GROUP INC - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBER and the CUSIP is G46843101. A total of 39 filers reported holding IBERE PHARMACEUTICALS in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q4 2022$514,540
+101789.1%
50,9950.0%0.00%
Q3 2022$505
-8.0%
50,995
-8.9%
0.00%
Q2 2022$549
-99.9%
55,9950.0%0.00%
Q1 2022$549,000
+1.3%
55,9950.0%0.00%
Q4 2021$542,000
-0.2%
55,9950.0%0.00%
Q3 2021$543,000
+2.5%
55,995
+2.3%
0.00%
Q2 2021$530,00054,7620.00%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q3 2021
NameSharesValueWeighting ↓
TEGEAN CAPITAL MANAGEMENT, LLC 137,133$896,4480.78%
Lynwood Capital Management Inc. 51,400$504,0000.56%
KRYGER CAPITAL Ltd 402,232$3,945,0000.27%
KIM, LLC 450,000$4,415,0000.21%
BASSO CAPITAL MANAGEMENT, L.P. 170,114$1,669,0000.18%
Knott David M Jr 36,000$353,0000.15%
Vestcor Inc 400,000$3,924,0000.15%
Castle Creek Arbitrage, LLC 253,446$2,486,0000.14%
GLAZER CAPITAL, LLC 509,934$5,002,0000.12%
PERISCOPE CAPITAL INC. 354,600$3,479,0000.09%
View complete list of IBERE PHARMACEUTICALS shareholders